ChromaDex Corporation
CDXC Real Time Price USDRecent trades of CDXC by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by CDXC's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Use of nicotinamide riboside, nicotinic acid riboside, and nicotinamide mononucleotide, reduced nicotinyl compounds, and nicotinoyl compound derivatives in infant formula for healthy development Dec. 13, 2022
-
Patent Title: Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof Mar. 15, 2022
-
Patent Title: Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof Feb. 08, 2022
-
Patent Title: Crystalline forms of nicotinoyl ribosides and derivatives thereof, and methods of preparation thereof Jan. 04, 2022
-
Patent Title: Nicotinamide riboside compositions for topical use in treating skin conditions Jun. 15, 2021
-
Patent Title: B-vitamin and amino acid conjugates of nicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof Mar. 02, 2021
-
Patent Title: Use of nicotinamide riboside, nicotinic acid riboside, and nicotinamide mononucleotide, reduced nicotinyl compounds, and nicotinoyl compound derivatives in infant formula for healthy development Dec. 08, 2020
-
Patent Title: Nicotinamide riboside compositions for topical use in treating skin conditions Jun. 23, 2020
-
Patent Title: Nicotinic acid riboside or nicotinamide riboside compositions, reduced derivatives thereof, and the use thereof to enhance skin permeation in treating skin conditions May. 07, 2019
-
Patent Title: Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as nad+ increasing precursors Jan. 22, 2019
-
Patent Title: Method for treating non-melanoma skin cancer by inducing udp-glucuronosyltransferase activity using pterostilbene Aug. 07, 2018
-
Patent Title: B-vitamin and amino acid conjugates ofnicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof Jun. 19, 2018
-
Patent Title: Method for inducing udp-glucuronosyltransferase activity using pterostilbene Sep. 23, 2014
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of CDXC in WallStreetBets Daily Discussion
Recent insights relating to CDXC
Recent picks made for CDXC stock on CNBC
ETFs with the largest estimated holdings in CDXC
|
Shareholder
|
Shares Held
|
|---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view CDXC Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.